IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring

Core Insights - The American Journal of Transplantation position paper emphasizes the importance of decentralized organ health testing, particularly highlighting the role of absolute quantification of donor-derived cell-free DNA (dd-cfDNA) as a diagnostic marker, which aligns with iMDx's GraftAssure family of assays [1][2] Industry Context - The STAR working group, a collaboration between the American Society of Transplantation and the American Society for Histocompatibility and Immunogenetics, advocates for high-quality, standardized decentralized dd-cfDNA testing to support multicenter studies and improve patient management [2][3] - The publication indicates a significant demand for decentralized testing solutions in the transplant community, which is seen as a positive indicator for iMDx's business strategy [2][3] Company Strategy - iMDx aims to provide industry-leading molecular diagnostic test kits that decentralize access to organ health testing for kidney transplant patients, targeting a market exceeding $1 billion for transplant rejection testing [3][4] - The company is focused on developing a high-quality assay with transparent quality control to enhance access to dd-cfDNA testing, which is viewed as a promising biomarker for transplant rejection [3][4] Product Overview - iMDx's GraftAssure product line includes: - GraftAssureCore: A laboratory-developed test currently reimbursed by CMS and performed at iMDx's CLIA-certified lab [6] - GraftAssureIQ: A research-use-only kit for non-clinical applications [6] - GraftAssureDx: An in vitro diagnostic kit under development for clinical decision-making [6]